Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Lynk Pharma Says JAK1 Inhibitor Effective for Ankylosing Spondylitis

publication date: Aug 24, 2023

Hangzhou Lynk Pharma announced positive topline data from a Phase II clinical trial of LNK01001, a JAK1 inhibitor, as a therapy for ankylosing spondylitis (AS). Lynk believes the candidate will offer better results because JAK1 belongs to a subgroup of the cytosolic tyrosine kinase Janus kinase (JAKs) family that is closely related to the pathogenesis of several autoimmune diseases. After 12 weeks of treatment, both the high and low dose groups of LNK01001 showed a statistically significant difference in the proportion of patients achieving an ASAS40 response, the trial’s primary endpoint. Specific data was not disclosed. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital